In case you haven’t heard, it’s the New Year. And over at The Week That Was (TWTW) headquarters we spent the last days of December working on a little project: TWTW 2.0, a new, improved version of the newsletter you know and love.
Don’t worry; you’ll still be hearing from us every week. We’ll be sharing a weekly roundup of our favorite stories along with an in-depth look at a top trend or landscape development. But, it will look a little different. We really hope you like it and welcome your thoughts along the way.
So with that, let’s get into it, 2019-style.
|THE WEEK THAT WAS|
Just in time for year-end, Senator Elizabeth Warren announced her intentions to join the 2020 race. Warren is a prominent proponent of drug pricing legislation, and recently introduced a new proposal that would allow the government to manufacture generic drugs in an effort to lower drug costs.
WSJ kicked off the New Year with some drug pricing coverage, reporting that three dozen drugmakers have raised the price on “hundreds of medicines,” with an average increase of 6.3%. Their coverage, and that of many other outlets, was based on an analysis from Rx Savings Solutions.
Robin Li, CEO of the Chinese tech company Baidu, sent a note to employees warning of economic restructuring in China and noted that “winter is coming.” How’s that for 2019 morale?
The Today Show covered the recent Bird Box Challenge phenomenon, after Netflix pleaded with fans not to try the challenge and “end up in the hospital due to memes.” Netflix, maybe Gronk can help out with this one too.
The team over at STAT penned a piece on the not-so-ideal conditions and exorbitant costs for attendees of next week’s JP Morgan conference in San Francisco.
Yes, the FDA is screening your calls
Two weeks into the partial government shutdown, we’re all starting to feel a little shutdown slump: fatigued by headlines and still somewhat confused as to what a partial shutdown really means. So we did some digging to understand exactly what the shutdown means for those of us in healthcare, particularly as it relates to the FDA.
What is a partial shutdown? At the end of last year, some government agencies were already funded for 2019. But many weren’t, and needed a bill passed to cover funding for about seven weeks (spoiler alert: that didn’t happen). The list of affected departments and agencies is extensive, including Department of Justice, Environmental Protection Agency, Department of Homeland Security and Federal Drug Administration.
Did you say FDA? Yup. Though their doors are still open, only 60% of FDA staffers are still at work and some FDA programs and services have been deemed non-essential. 😐
Will products still be reviewed and approved during the shutdown? It depends on the therapy, its review schedule and if it’s being funded through user fees. Here’s a breakdown of what’s on hold, with a little help from Scott Gottlieb’s Twitter feed:
- User fee funded drug review. Because the FDA can't collect any user fee payments specifically for fiscal year 2019, they “can't accept new applications for products under user fee programs: PDUFA, GDUFA, BsUFA, MDUFA, ADUFA, AGDUFA.”
- Non-emergency CBER and CDER work. For CBER, this applies to work regulated under sec. 361 (pg. 415) of the Public Health Safety Act (whole blood, blood components for transfusion, allergenic extracts and HCT/Ps). For CDER, this applies to “OTC monograph drug activities.”
- Pending, non-emergency INDs. The 30-day clock for these has essentially been put on pause and will start again when the shutdown is over. New INDs that “relate to the safety of individuals who are participating in clinical trials” are deemed emergency and will still be reviewed.
Essentially, per the Alliance for a Stronger FDA, some portion of the drug review process will be put on hold, but NDAs that are already filed and paid for should still be reviewed though “agency time frames may slip.” Or, put another way by our R&RM colleague and former FDA Associate Commissioner, Peter Pitts, as long as the shutdown lasts, “If you’re dealing with the FDA, take the rest of the day off.”
Can Gottlieb go rogue and ignore the limitations? No. Defying the shutdown and continuing business as usual would be considered a felony under the Anti-Deficiency Act.
Still have questions about how the shutdown might affect your work with the FDA? Drop us a note and we’ll put you in touch Peter Pitts (who is working).
Who wrote this? This issue was written by TWTW managing-editor and R&RM strategist Dana Davis, who is powered by Starbucks red-eyes. This issue was edited by R&RM practice head Meg Alexander, who managed to get a hotel room in San Francisco and will be on the ground at JPM next week. Syneos Health Communications' Reputation & Risk Management Practice is a team of healthcare communications consultants, policy-shapers and crisis response specialists. We provide unique solutions to the evolving communications challenges in today’s healthcare industry, using evidence-based approaches to help our clients successfully navigate the most sensitive of situations.
Got thoughts? Contact Dana
Have any friends? Let us know and we'll sign them up for TWTW.
Feeling nostalgic? We get it. Check out old TWTW issues here.
Image credits: Elizabeth Warren by Lorie Shaull from the Noun Project, golden gate bridge by Hea Poh Lin from the Noun Project
And now please enjoy this disclaimer that prevents our team from getting in a heap of trouble: This report may contain links to external or third party websites. These links are provided solely for your convenience. Links taken to other sites are done so at your own risk and Syneos Health accepts no liability for any linked sites or their content. Syneos Health makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, the information contained on them or the suitability or quality of any of their products or services. Syneos Health does not authorize the infringement of any intellectual property rights contained in material offered through these linked sites. Please refer to the use agreement and/or copyright statements of any external site you visit, or the terms and conditions of any externally provided web site for instructions, restrictions, and guidelines. If you have a question, please contact the webmaster of the external site.